Breaking News Instant updates and real-time market news.

AKBA

Akebia

$3.93

-0.18 (-4.38%)

04:55
09/05/19
09/05
04:55
09/05/19
04:55

Akebia management to meet with JPMorgan

Meeting to be held in Boston on September 5 hosted by JPMorgan.

  • 05

    Sep

  • 09

    Sep

AKBA Akebia
$3.93

-0.18 (-4.38%)

05/10/19
PIPR
05/10/19
NO CHANGE
Target $22
PIPR
Overweight
Akebia shares should be bought at the open, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends purchase of Akebia Therapeutics (AKBA) shares at today's opening bell. Despite "one of the worst communication jobs we have ever witnessed with respect to a major data event," FibroGen's (FGEN) roxadustat data appear positive in that the drug has shown a statistically non-inferior safety profile versus controls in both pre-dialysis and dialysis settings, Raymond tells investors in a research note. The analyst believes that should roxadustat prove safe as well as efficacious, the agent should pave the way for the hypoxia-inducible-factor class as a novel anemia correction approach in renal disease. While FibroGen "seemed almost determined to confuse investors with their presentation of the data, we think that thesis remains intact," says the analyst. Raymond keeps an Overweight rating on Akebia with a $22 price target.
06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper says buy Akebia before market figures out competitive positoin
After hosting an investor call with Akebia Therapeutics (AKBA) CEO John Butler, Piper Jaffray analyst Christopher Raymond thinks vadadustat's competitive position relative to FibroGen's (FGEN) roxadustat is "stronger, not weaker now." As such, the analyst recommends buying shares of Akebia "before the market begins to figure this out." Raymond left the call incrementally confident in vadadustat "on a number of levels," namely its approvability given Akebia's alignment with FDA on trial design and statistical analysis. He keeps an Overweight rating on the shares with a $22 price target.
07/24/19
HCWC
07/24/19
NO CHANGE
Target $19
HCWC
Buy
Akebia shares at 'excellent entry point,' says H.C. Wainwright
After Akebia (AKBA) announced that its Japanese partner on vadadustat has submitted a New Drug Application in Japan that supports approval for anemia due to chronic kidney disease in both non-dialysis and dialysis patients, H.C. Wainwright analyst Ed Arce noted that this represents the first regulatory submission for vadadustat. The current valuation, with shares trading near 52-week lows, presents "an excellent entry point" given that the primary bear thesis depends on the first-to-market advantage of Fibrogen's (FGEN) roxadustat, which Arce views as "fundamentally flawed," he tells investors. In light of the JNDA submission, as well as the current timeline, Arce pushed back his U.S. and EU market launch and initial sales estimates to early 2022 and trimmed his price target on Akebia shares to $19 from $21, but he keeps a Buy rating on the stock.
08/08/19
PIPR
08/08/19
NO CHANGE
Target $22
PIPR
Overweight
Akebia's Auryxia 'a nice little growth story,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and $22 price target on Akebia's shares following the company's Q2 update. While the analyst is "gratified" to see the shares up 11% on a robust Auryxia print, the analyst believes this company still has an EV $300M, despite possessing a $130M/year approved drug, and a potential $1B product - vadadustat - with Phase 3 readouts next year. Raymond thinks the totality of the data would indicate that, despite being the second HIF to the market, vadadustat is differentiated enough, and the market is large enough that vadadustat has blockbuster potential. In the meantime, he would argue this stock's current valuation is more than justified by Auryxia alone

TODAY'S FREE FLY STORIES

EDPFY

Energias de Portugal

$0.00

(0.00%)

19:56
10/20/19
10/20
19:56
10/20/19
19:56
Upgrade
Energias de Portugal rating change  »

Energias de Portugal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

ARWR

Arrowhead

$35.98

-0.63 (-1.72%)

19:54
10/20/19
10/20
19:54
10/20/19
19:54
Recommendations
Arrowhead analyst commentary  »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

, FB

Facebook

$185.96

-4.435 (-2.33%)

19:31
10/20/19
10/20
19:31
10/20/19
19:31
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

BA

Boeing

$344.09

-25.04 (-6.78%)

FB

Facebook

$185.96

-4.435 (-2.33%)

T

AT&T

$38.46

0.64 (1.69%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$130.91

-1.46 (-1.10%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

GMVHF

GVC Holdings

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

CPTA

Capitala Finance

$9.11

0.13 (1.45%)

19:23
10/20/19
10/20
19:23
10/20/19
19:23
Downgrade
Capitala Finance rating change  »

Capitala downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

GM

General Motors

$36.19

-0.01 (-0.03%)

, F

Ford

$9.29

0.18 (1.98%)

19:13
10/20/19
10/20
19:13
10/20/19
19:13
Periodicals
GM contract terms may be hard for rivals, NY Times says »

General Motors (GM) made…

GM

General Motors

$36.19

-0.01 (-0.03%)

F

Ford

$9.29

0.18 (1.98%)

FCAU

Fiat Chrysler

$13.22

0.085 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

TRI

Thomson Reuters

$66.73

-0.08 (-0.12%)

19:09
10/20/19
10/20
19:09
10/20/19
19:09
Hot Stocks
Thomson Reuters issues statement on CEO succession planning »

Thomson Reuters has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

T

AT&T

$38.46

0.64 (1.69%)

, CMCSA

Comcast

$45.58

-0.36 (-0.78%)

16:45
10/20/19
10/20
16:45
10/20/19
16:45
On The Fly
Box Office Battle: 'Maleficent 2' wins weekend with just $36M »

"Box Office Battle" is…

T

AT&T

$38.46

0.64 (1.69%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$59.23

-0.83 (-1.38%)

LGF.A

Lionsgate

$8.47

-0.13 (-1.51%)

LGF.B

Lionsgate

$7.96

-0.11 (-1.36%)

DIS

Disney

$130.91

-1.46 (-1.10%)

VIAB

Viacom

$22.05

-0.56 (-2.48%)

VIA

Viacom

$24.80

-0.8 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

FB

Facebook

$185.96

-4.435 (-2.33%)

16:16
10/20/19
10/20
16:16
10/20/19
16:16
Periodicals
Facebook open to currency-pegged stablecoins, Reuters reports »

Facebook, facing growing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

WYNN

Wynn Resorts

$113.55

-0.49 (-0.43%)

16:12
10/20/19
10/20
16:12
10/20/19
16:12
Periodicals
Ex-Wynn Resorts worker claims company spied on him, WSJ reports »

A former Wynn Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

16:01
10/20/19
10/20
16:01
10/20/19
16:01
Periodicals
SoftBank seeking to avoid WeWork's liabilities with new investment, Reuters says »

SoftBank (SFTBY) is…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

JPM

JPMorgan

$120.60

0.21 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 21

    Nov

  • 14

    Jan

GM

General Motors

$36.19

-0.01 (-0.03%)

15:53
10/20/19
10/20
15:53
10/20/19
15:53
Periodicals
GM strike continues, pain felt by Midwest workers deepens, WSJ says »

With the strike at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

BA

Boeing

$344.09

-25.04 (-6.78%)

15:43
10/20/19
10/20
15:43
10/20/19
15:43
Periodicals
Boeing expresses regret over ex-pilot's 737 Max messages, Reuters says »

Boeing said that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ED

Consolidated Edison

$91.54

0.22 (0.24%)

, MA

MasterCard

$270.90

-5.74 (-2.07%)

15:38
10/20/19
10/20
15:38
10/20/19
15:38
Hot Stocks
MasterCard expands Bill Pay Exchange partners »

Mastercard (MA) has…

ED

Consolidated Edison

$91.54

0.22 (0.24%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

LAZ

Lazard

$37.09

0.06 (0.16%)

15:33
10/20/19
10/20
15:33
10/20/19
15:33
Hot Stocks
Lazard announces resignation of Deputy CEO of Financial Advisory »

Lazard announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 07

    Nov

  • 07

    Nov

ALXN

Alexion

$98.41

-1.53 (-1.53%)

15:25
10/20/19
10/20
15:25
10/20/19
15:25
Hot Stocks
Alexion ULTOMIRIS receives FDA approval for Atypical Hemolytic Uremic Syndrome »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 04

    Nov

  • 07

    Dec

BRBR

BellRing Brands

$16.65

-0.04 (-0.24%)

, POST

Post Holdings

$100.65

-0.8 (-0.79%)

09:49
10/20/19
10/20
09:49
10/20/19
09:49
On The Fly
Opening Day: BellRing climbs after $480M IPO »

BellRing Brands (BRBR)…

BRBR

BellRing Brands

$16.65

-0.04 (-0.24%)

POST

Post Holdings

$100.65

-0.8 (-0.79%)

IPHA

Innate Pharma

$6.05

0.19 (3.24%)

KRAT

Karat Packaging

$0.00

(0.00%)

ONEW

OneWater Marine

$0.00

(0.00%)

BRP

BRP Group

$0.00

(0.00%)

PGNY

Progyny

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 07

    Dec

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

BA

Boeing

$344.09

-25.04 (-6.78%)

08:31
10/19/19
10/19
08:31
10/19/19
08:31
Periodicals
Boeing recovery getting 'a lot more complicated,' Barron's says »

Boeing shares fell on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GMVHF

GVC Holdings

$0.00

(0.00%)

08:27
10/19/19
10/19
08:27
10/19/19
08:27
Periodicals
GVC Holdings looking like 'a good bet,' Barron's says »

GVC Holdings' stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$22.98

-0.94 (-3.93%)

08:19
10/19/19
10/19
08:19
10/19/19
08:19
Periodicals
Street sees National Vision as a buy, some shorts disagree, Barron's says »

National Vision has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$167.11

2.3 (1.40%)

, HUM

Humana

$289.59

4 (1.40%)

08:13
10/19/19
10/19
08:13
10/19/19
08:13
Periodicals
Healthcare stocks getting 'back on their feet,' Barron's says »

The sector is the second…

CI

Cigna

$167.11

2.3 (1.40%)

HUM

Humana

$289.59

4 (1.40%)

UNH

UnitedHealth

$245.59

1.84 (0.75%)

WCG

WellCare

$274.54

0.09 (0.03%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$123.03

1.47 (1.21%)

TEVA

Teva

$7.50

-0.26 (-3.35%)

AZN

AstraZeneca

$43.86

-0.25 (-0.57%)

BMY

Bristol-Myers

$53.02

0.6 (1.14%)

LLY

Eli Lilly

$108.68

0.24 (0.22%)

GSK

GlaxoSmithKline

$42.52

0.04 (0.09%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

MRK

Merck

$84.68

0.88 (1.05%)

NVS

Novartis

$86.86

-0.395 (-0.45%)

PFE

Pfizer

$36.46

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$46.13

-0.43 (-0.92%)

ANTM

Anthem

$249.55

0.3 (0.12%)

CVS

CVS Health

$66.17

-0.31 (-0.47%)

CNC

Centene

$46.92

-0.28 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 14

    Nov

  • 18

    Nov

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

08:03
10/19/19
10/19
08:03
10/19/19
08:03
Periodicals
ConocoPhillips stock looking cheap following selloff, Barron's says »

At a time when Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 19

    Nov

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

, NFLX

Netflix

$275.40

-17.88 (-6.10%)

08:00
10/19/19
10/19
08:00
10/19/19
08:00
Periodicals
Comcast stacking up better than investors might expect, Barron's says »

If cord-cutting…

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

T

AT&T

$38.46

0.64 (1.69%)

DIS

Disney

$130.91

-1.46 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

AKS

AK Steel

$2.45

0.055 (2.30%)

, MT

ArcelorMittal

$14.58

0.03 (0.21%)

07:41
10/19/19
10/19
07:41
10/19/19
07:41
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

AKS

AK Steel

$2.45

0.055 (2.30%)

MT

ArcelorMittal

$14.58

0.03 (0.21%)

NUE

Nucor

$51.69

-0.11 (-0.21%)

STLD

Steel Dynamics

$28.71

-0.04 (-0.14%)

TMST

TimkenSteel

$5.42

-0.015 (-0.28%)

X

U.S. Steel

$10.72

0.1 (0.94%)

GM

General Motors

$36.19

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 31

    Oct

  • 01

    Nov

AAVMY

ABN Amro

$0.00

(0.00%)

, BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

04:55
10/19/19
10/19
04:55
10/19/19
04:55
Conference/Events
Institute of International Finance to hold annual meeting »

2019 IIF Annual Meeting…

AAVMY

ABN Amro

$0.00

(0.00%)

BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

BCS

Barclays

$8.48

0.11 (1.31%)

BLK

BlackRock

$445.26

-5.56 (-1.23%)

BNPQY

BNP Paribas

$0.00

(0.00%)

C

Citi

$69.76

0.16 (0.23%)

CAIXY

CaixaBank

$0.00

(0.00%)

CIB

Bancolombia

$49.65

0.12 (0.24%)

CS

Credit Suisse

$12.34

0.045 (0.37%)

EV

Eaton Vance

$44.07

-0.49 (-1.10%)

GS

Goldman Sachs

$206.61

0.13 (0.06%)

HSBC

HSBC

$38.72

-0.165 (-0.42%)

JPM

JPMorgan

$120.60

0.21 (0.17%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

MCO

Moody's

$217.41

-1.33 (-0.61%)

MS

Morgan Stanley

$43.70

0.25 (0.58%)

NYT

New York Times

$29.76

0.21 (0.71%)

PYPL

PayPal

$101.25

-2.38 (-2.30%)

RBS

RBS

$6.14

0.205 (3.46%)

RY

Royal Bank of Canada

$81.49

0.38 (0.47%)

SMFG

Sumitomo Mitsui

$6.87

-0.04 (-0.58%)

SPGI

S&P Global

$250.62

-2.15 (-0.85%)

STT

State Street

$63.40

3.69 (6.18%)

UBS

UBS

$11.35

0.09 (0.80%)

V

Visa

$175.83

-2.11 (-1.19%)

ZURVY

Zurich Insurance

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 10

    Nov

  • 12

    Nov

  • 21

    Nov

  • 04

    Dec

  • 10

    Dec

  • 07

    Jan

  • 14

    Jan

  • 14

    Jan

STT

State Street

$63.40

3.69 (6.18%)

20:09
10/18/19
10/18
20:09
10/18/19
20:09
Upgrade
State Street rating change at Keefe Bruyette »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.